ophthalmologytimes15h
Sling Therapeutics announces topline efficacy and safety data from Phase 2b/3 LIDS trial on linsitinib
Linsitinib showed significant efficacy in reducing proptosis in TED patients, with a 52% responder rate at 150mg BID. The ...
ophthalmologytimes16h
HelpMeSee announces new training partnerships, simulation training sites
Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...